Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial

Abstract

Epidemiological studies have suggested that adipsin and visfatin are associated with the development of type 2 diabetes. This is the first study to investigate the effects of supplementation with purified anthocyanins on serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes. A total of 160 participants with prediabetes or newly diagnosed diabetes (40-75years old) were given 320mg anthocyanins or placebo daily for 12weeks in a randomized trial. Serum adipsin, serum visfatin, lipids and glycated hemoglobin A1c (HbA1c) were measured. The areas under the curve (AUCs) for glucose, insulin and C-peptide were determined before-and after-treatment by a standard 3-h 75g oral glucose tolerance test (OGTT). Relatively significant increases in serum adipsin (net change 0.15µg/mL [0.03, 0.27], p = 0.018) and decreases in visfatin (-3.5ng/mL [-6.69, -0.31], p = 0.032) were observed between the anthocyanins and placebo groups. We also observed significant improvements in HbA1c (-0.11% [-0.22, -0.11], p = 0.033), apolipoprotein A-1 (apo A-1) (0.12g/L [0.03, 0.21], p = 0.012) and apolipoprotein B (apo B) (-0.07g/L [-0.14, -0.01], p = 0.033) in response to the anthocyanins intervention. Purified anthocyanins supplementation for 12weeks increased serum adipsin and decreased serum visfatin in patients with prediabetes or newly diagnosed diabetes. Trial registration ClinicalTrials.gov, identifier: NCT02689765.